Liver Transplantation:  Information on allocation of livers, recurrent HCV after transplantation, effect of race/ethnicity, immunosuppressant drugs, post transplant HCV disease progression, and pediatric issues.

 

·        Allocation/General

o       589. Non-standard livers to liver transplant candidates: a fatal combination in liver transplantation

o       594. Experience with Pre-Recovery Liver Biopsies in Potential Deceased Liver Donors (updated October 29, 2006)

o       773. Can we expand the pool of organ donors? Use of livers from anti-HBc+ and/or anti-HCV+ organ donors (updated October 31, 2006)

 

·        Allocation/MELD

o       577. Rates of Special Case MELD Exception Awards and Liver Transplant Waiting List Death Vary by UNOS Region

o       580. Effects on survival of listing vs not listing patients with low MELD scores (updated October 29, 2006)

o       581. Impact of MELD Allocation on Post-OLT Renal Failure: Analysis of the UNOS Database (updated October 31, 2006)

o       593. Post Liver Transplant Quality of Life as a function of pre-transplant MELD score and other variables

o       604. MELD-XI: a rational approach to “sickest first” liver transplantation in cirrhotic patients requiring anticoagulant therapy (updated October 29, 2006)

o       608. MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation (updated October 29, 2006)

o       616. Cost Analysis of Liver Transplantation According to MELD Score (updated October 29, 2006)

o       626. Renal Insufficiency after Liver Transplantation in the MELD Era Compared to the Pre-MELD Era (updated November 1, 2006)

o       636. Age, creatinine and liver function but not MELD predict 6-month survival after liver transplantation: clinical and economic considerations (updated October 29, 2006)

o       712. Etiology of cirrhosis has an impact on survival predicted by MELD-score (updated October 29, 2006)

o       747. The Model for End-stage Liver Disease (MELD) Score is Predictive of Intensive Care Unit (ICU) Mortality in Patients with Cirrhosis (updated October 30, 2006)

 

·        Allocation/MILAN

o       587. Liver Transplantation for Hepatocellular Carcinoma: Validation of the Milan Criteria using the UNOS database

o       627. Evidence that an extension of Milan criteria to 5-5 criteria does not impact survival nor HCC recurrence after liver transplantation for hepatocellular carcinoma

 

·        General

o       1. Outcomes of patients with hepatitis B (HBV) who developed viral breakthrough or genotypic resistance to antiviral therapy while on the liver transplant (OLT) waiting list.

o       502. Simultaneous Provision of Pre-operative Palliative Care for Patients Awaiting Liver Transplantation (updated October 29, 2006)

o       503. Nursing attitudes towards liver transplant: Gap between perceptions and accepted standards (updated October 29, 2006)

o       508. Body Composition Analysis in Peri Transplant Patients (updated October 29, 2006)

o       579. Effect of gender mismatch on acute cellular rejection and graft failure in liver transplant recipients (updated October 29, 2006)

o       612. Does indication of alcoholic liver disease influence the long-term results of liver transplantation?

o       618. Does pre-transplant abstinence duration influence the results of liver transplantation for alcoholic liver disease : an attempt of meta-analysis (updated October 29, 2006)

o       622. Predictors of renal failure in patients undergoing liver transplantation for chronic liver disease.

o       629. Transjugular Intrahepatic Portosystemic Shunts (TIPS) are Associated with a High 1-year Mortality in Liver Transplant Recipients (updated October 31, 2006)

o       631. Prevalence and predominant factor of low bone mineral density among patients awaiting liver transplantation

o       637. Rate Of Progression Of Portopulmonary Hypertension Over A Short Time Interval In Patients Awaiting Liver Transplant (updated October 29, 2006)

o       788. Prevalence of serum antinuclear antibodies (ana) after liver transplant in hcv and hbv recipients is associated with different clinical profiles

 

·        Immunosuppression

o       576. Multicenter randomized hepatitis C (HCV) - three trial post liver transplantation (OLT): two-year interim report

o       582. Randomized Prospective Study Suggesting Worse Outcomes For Complete Steroid Avoidance in Liver Transplantation

o       583. Mycophenolate mofetyl (MMF) monotherapy is an attractive strategy in liver transplant recipients with severe side effects of calcineurin inhibitors (CNI) (updated October 29, 2006)

o       602. Tacrolimus versus Cyclosporine Based Immunosuppression in Hepatitis C Patients after Liver Transplantation: Long-Term Follow-up of a Randomized Controlled Trial (updated October 29, 2006)

o       611. Steroid-free Immunosuppression in Pediatric Liver Transplantation: A pilot study examining efficacy for prevention of graft rejection (updated October 29, 2006)

o       625. A Randomized Controlled Trial of Cyclosporine Vs Tacrolimus Immunosuppression in Patients Receiving Pegylated Interferon and Ribavirin for Recurrence Hepatitis C Virus Infection after Liver Transplantation: The Preliminary Results

 

·        Liver Cancer

o       9. Liver Transplantation for Hepatocellular Carcinoma: A 5-year Prospective Study Validating Expanded Criteria Applied to Pre-operative Imaging

o       640. Liver transplantation for hepatocellular carcinoma over two decades. A single center experience

 

·        Living Liver Donors

o       10. Outcomes of adult living donor vs. deceased donor liver transplantation from the time of listing

o       11. Use of a Computerized Assessment to Measure Patient Competency to Provide Informed Consent for Living Liver Donation: Findings from the Adult to Adult Living Donor Liver Transplantation Cohort Study (A2ALL)

o       642. Histological abnormalities found on liver biopsies of appearently healthy potential liver donors (updated October 29, 2006)

o       643. HLA and Living-Donor Liver Transplantation Outcomes – An Analysis of the OPTN Database

o       644. Evaluation for hepatic steatosis in Japanese living liver donors and outcome of dietary intervention (updated October 29, 2006)

o       646. Liver regeneration in living donors of right and left liver grafts until 1 year

o       648. Comparison of Complication Rates in Recipients of Living Donor and Deceased Donor Liver Transplants: Findings from the Adult to Adult Living Donor Liver Transplantation Cohort Study (A2ALL) (updated October 29, 2006)

o       649. The Impact of a Donor Advocacy Committee on the Evaluation Process of Living Liver Donors (updated October 29, 2006)

 

·        Pediatric

o       603. Growth and final height after pediatric liver transplantation in relation to age and underlying disease (updated October 29, 2006)

o       662. Liver Injury From Repeated Dosing of Acetaminophen (APAP) in Pediatric Patients (updated October 29, 2006)

o       672. Predictors of Long-Term Hypertension Following Pediatric Orthotopic Liver Transplantation: A Single Center Longitudinal Study of 419 Patients

o       673. Growth Patterns in Children Following Liver Transplantation (updated October 29, 2006)

o       674. Renal function is decreased after pediatric liver transplantation: an interim report from the Studies In Pediatric Liver Transplantation (SPLIT) renal function working group

 

·        Post Transplant

o       7. THE PAN-Caspase Inhibitor, IDN-6556, Attenuates Human Liver Preservation Injury

o       590. Post-Transplant Ascites Typically Occurs in the Absence of Significant Fibrosis (updated October 29, 2006)

o       592. Outcome of liver transplantation in patients with glutathione S-transferase T1 donor/recipient mismatch and de novo immune hepatitis (updated October 29, 2006)

o       597. Sexual dysfunction in female patients before and after liver transplantation (LT) (updated October 29, 2006)

o       606. The Development of De Novo Autoimmune Hepatitis (Immune-Mediated Hepatitis) and its Effect on Outcome in Patients With HCV Post-Liver Transplantation (updated October 29, 2006)

o       609. Predictors of Employment in Liver Transplant Recipients

o       777. Diabetes and Immunohistochemical Staining for Oxidative Damage in Liver Tissue are Associated with Fibrosis Progression in Hepatitis C after Liver Transplantation.

o       1298. Increased activity of regulatory T cells in recurrent hepatitis C after liver transplantation.  

 

o       Recurrence

§        5. Methylenetetrahydrofolate Reductase C677T Gene Polymorphism and Early Graft Fibrosis Progression among Liver Transplantation Recipients with Recurrent Hepatitis C

§        229. HCV infection is associated with progressive insulin resistance in liver transplant recipients

§        348. Progression of Fibrosis and Interferon Treatment in Liver Transplant Recipients with Hepatitis C Infection

§        610. CCR2 V64I Polymorphism: A risk factor for patients suffering HCV after orthotopic liver transplantation (updated October 29, 2006)

§        633. The Development of Hepatic Granulomas in Patients Receiving Pegylated Interferon Therapy for Recurrent HCV Post Liver Transplantation (updated October 29, 2006)

§        774. Detection of HCV antigens (HCV-Ag) in early post liver transplant (LT) graft biopsies predicts recurrent hepatitis C after 1 year post LT in patients transplanted for HCV related liver disease

§        775. Early HCV RNA levels and “Super-recurrence” predict advanced allograft fibrosis at 1-year in patients undergoing liver transplant for HCV

§        776. Recurrence risk score predicts cumulative increase in hepatitis C recurrence after liver transplantation (updated October 30, 2006)

§        778. Sustained Viral Response Using Peg IFN alfa-2b Plus Ribavirin in Patients with Recurrent Hepatitis C after Liver Transplantation (updated October 30, 2006)

§        780. Impact of Extended Criteria Donor on Hepatitis C recurrence following Liver Transplantation (updated October 30, 2006)

§        781. Sustained virological response to antiviral therapy for recurrent HCV post liver transplant favorably influences histological progression

§        783. Immunohistochemical perforin staining allows differentiation between hepatitis C recurrence and rejection post-liver transplant

§        784. Steatosis In Post Transplant Liver Biopsies May Herald Recurrence Of Hepatitis C Genotype 3

§        785. Genotype and choice of calcineurin inhibitor influence response to antiviral therapy in liver transplant recipients treated for recurrent HCV

§        787. Impact of the recurrence of hepatitis C in quality of life after liver transplantation

§        789. Adherence to the 80/80/80 rule in treatment of HCV recurrence after OLT is strongly associated with sustained virologic response (SVR)

 

·        Race/Ethnicity

o       605. Racial Differences in Liver Transplantation and Mortality in Hospitalized Cirrhotic Patients with Portal Hypertension

o       617. Comparative Analysis of Ethnic Disparities in Liver Transplantation for Pediatric and Adult population